What is Zhejiang Huahai Pharmaceutical Co., Ltd.'s (600521.SS) StockRank?

MoatMap's StockRank for Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) is 32/100, with a Sell signal. This is a composite score combining Quality (45), Value (30), and Momentum (45) factor ranks across MoatMap's 20,000+ stock universe.

Does Zhejiang Huahai Pharmaceutical Co., Ltd. have an economic moat?

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Zhejiang Huahai Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Zhejiang Huahai Pharmaceutical Co., Ltd. in?

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600521.SS

Sell

Zhejiang Huahai Pharmaceutical Co., Ltd. · Healthcare · China · $3.7B · Avg Vol: $105M/d

StockRank

Get insider-trade alerts

P/E (TTM)

68.3x

ROE

3.3%

D/E

0.9x

Dividend %

0.6%

COMPANY DESCRIPTION

Zhejiang Huahai Pharmaceutical Co., Ltd. manufactures active pharmaceutical ingredients (APIs) and finished dosage form (FDF) generic drugs, specializing in cardiovascular and CNS therapies. It is one of China's leading exporters of formulations to regulated Western markets, supported by extensive FDA approvals. The company operates as a globally integrated generic drug manufacturer with strong R&D capabilities and large-scale API production facilities.

FINANCIAL SUMMARY (CNY)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	8.3B	8.3B	9.5B	8.6B	1.3%	8.6B	9.5B	10.4B	9.8%
EPS (CNY)	0.81	0.57	0.77	0.18	-39.4%	0.24	—	—	—
Shares	1.5B	1.5B	1.5B	1.5B	+0.9%	1.5B	—	—	—
Debt	6.9B	7.0B	7.5B	8.0B	5.4%	8.7B	—	—	—
Equity	7.5B	8.1B	8.9B	9.4B	7.8%	—	—	—	—
Op CF	1.2B	2.2B	2.2B	1.2B	-0.3%	1.4B	—	—	—
Inv CF	-2.4B	-1.6B	-1.9B	-1.9B	—	—	—	—	—
Fin CF	609.0M	-644.2M	-132.9M	617.1M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+1.0%

SMA 50SMA 200

$2.46

RSI (14)

35.6

52W High

$4.13

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

5.5%59.2

ROE

3.3%53.4

GP/Assets

22.7%51.7

Op. Margin

13.2%71.5

FCF/Assets

-3.4%38.3

Piotroski

431.8

Int. Cover

2.9x47.2

D/E Ratio

0.88x17.2

Current Ratio

1.01x11.6

Value

P/E (TTM)

68.3x13.8

EV/EBITDA

21.2x29.8

P/FCF

—N/A

P/B

2.5x51.4

P/S

2.9x59.3

Div Yield

0.6%13.5

Momentum

52W High %

59%34.2

RS 6M

—N/A

SMA 50/200

1.00x59.3

EPS Rev 4W

+1.2%51.0

EPS Rev 12W

+1.3%60.0

EPS Improve

+38%48.1

Q Growth

36%68.0

FUNDAMENTALS

Market Cap

$3.7B

P/E (Forward)

49.7x

Gross Margin

56.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600521.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600521.SS	Zhejiang Huahai Pharmaceutical Co., Ltd.(you)	$3.7B	32	Sell
600518.SS	Kangmei Pharmaceutical Co., Ltd.	$2.8B	30	Sell
000661.SZ	Changchun High-Tech Industry (Group) Co., Ltd.	$4.8B	34	Sell
300199.SZ	Hybio Pharmaceutical Co., Ltd.	$3.1B	37	Hold
002294.SZ	Shenzhen Salubris Pharmaceuticals Co., Ltd.	$5.3B	30	Sell
002317.SZ	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	$3.2B	38	Hold
688131.SS	Shanghai Haoyuan Chemexpress Co., Ltd.	$3.1B	41	Hold
300723.SZ	ApicHope Pharmaceutical Group Co., Ltd.	$2.4B	28	Sell
300558.SZ	Betta Pharmaceuticals Co., Ltd.	$3.1B	44	Hold
6887.HK	Sunshine Lake Pharma Co., Ltd.	$2.9B	45	Hold

Peer medians: ROE 4.5% · P/E 28.9x · Gross margin 52.6%

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS): Stock Score Summary

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) has a MoatMap StockRank of 32/100 based on Quality (45/100), Value (30/100), and Momentum (45/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$2.46
Market Cap	$3.7B
P/E (TTM)	68.33
P/E (Forward)	49.70
Price/Book	2.54
Return on Equity	3.3%
Return on Invested Capital	5.5%
Debt/Equity	0.88x
Gross Margin	56.3%
Operating Margin	13.2%
Revenue Growth	-1.4%
Dividend Yield	0.6%
Free Cash Flow	$-108M

Zhejiang Huahai Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Zhejiang Huahai Pharmaceutical Co., Ltd.’s (600521.SS) StockRank?: MoatMap’s StockRank for Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) is 32/100, with a Sell signal. It is a composite of Quality (45), Value (30), and Momentum (45) factor ranks across MoatMap’s 20,000+ stock universe.
Does Zhejiang Huahai Pharmaceutical Co., Ltd. have an economic moat?: Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Zhejiang Huahai Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Zhejiang Huahai Pharmaceutical Co., Ltd. in?: Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).